Trodelvy Dosage and Administration

 Note: It is not advisable to substitute Trodelvy injection for or use with other medicinal products that are known for containing irinotecan or its active metabolite SN-38.



Proposed Dosage of Trodelvy:

The proposed dosage of Trodelvy is 10 mg/kg. The dosage needs to be administered as an intravenous infusion once a week on the 1st & 8th Days of 21-day treatment cycles. Continue treatment with trodelvy 180 mg until the disease progresses or has unacceptable adverse reactions.

Avoid administering Trodelvy at doses of more than 10 mg/kg. The medicine Trodelvy is for intravenous use only. This medicinal product is not for use as an intravenous push or bolus. 

Initial Infusion: Administer trodelvy infusion over three hours. Assess respective patients throughout the infusion and a minimum of 30 minutes following the initial dose for signs-symptoms of infusion-related reactions. 

Subsequent Infusions: Administer trodelvy infusion over 60-120 minutes in case previous infusions were tolerated. Assess respective patients throughout the infusion and for at least 30 minutes after infusion.

Premedication:

Before each dose of Trodelvy injection, premedication to prevent infusion reactions and chemo-induced vomiting and nausea is recommended. 

  • Patients should be premedicated with antipyretics, H1 & H2 blockers before each infusion, and corticosteroids may be considered for all those who had earlier infusion reactions.
  • The respective patients should be premedicated with a 2 or 3-medicine combination regimen.

Reference: https://www.trodelvy.com/

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

Lenvatinib Medication Guide

Lenvatinib is recommended for treating patients with locally recurrent, progressive, metastatic, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), together with everolimus for advanced renal cell carcinoma and for hepatocellular carcinoma.  Here are a few important points for patients before taking Lenvatinib:- Female patients who are able to become pregnant must use an effective method of birth control while on the treatment with lenvatinib and for at least 2 weeks after its last dose. Discuss with your doctor about the birth control methods you can use during this time. Lenvatinib is taken at the same time each and every day. If a patient misses any dose, and it cannot be consumed within 12 hours, then that dose must be skipped and the next dose should be consumed at the usual time of administration. The recommended dose is lenvatinib 24 mg (two lenvatinib 10 mg capsules and one lenvatinib 4 mg capsule) orally, taken once in a day, either with or wit
Read more

Difference Between Multiple Myeloma And Leukemia

Image
What is multiple myeloma:  This is also known as plasma cell myeloma or Kahler's disease. It is a cancer in plasma cells that typically produce antibodies. When there is only one tumor present it is called as plasmacytoma and when more than one then called as multiple myeloma. The main cause of myeloma is unknown but the major risk factors are obesity,  inheritance chemicals, radiation, etc. With the effect of cancer, there is an abnormality in plasma cells that produces abnormal antibodies that can cause kidney problems. At the initial stage, there is no sign and symptoms but with the advancement of time bone pain, bleeding, anemia and frequent infections are the common symptoms. Multiple myeloma is diagnosed with the help of blood or urine tests or bone marrow biopsy. And the medication of multiple myeloma includes: Chemotherapy- There are several drugs that are used in the treatment of multiple myeloma such as doxorubicin, etoposide, cisplatin, cyclophosphamide, e
Read more